BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 10816026)

  • 1. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
    Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
    Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.
    Luznik L; Jalla S; Engstrom LW; Iannone R; Fuchs EJ
    Blood; 2001 Dec; 98(12):3456-64. PubMed ID: 11719388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
    Mariotti J; Taylor J; Massey PR; Ryan K; Foley J; Buxhoeveden N; Felizardo TC; Amarnath S; Mossoba ME; Fowler DH
    Biol Blood Marrow Transplant; 2011 May; 17(5):620-31. PubMed ID: 21130889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.
    Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning.
    Kuwatani M; Ikarashi Y; Mineishi S; Asaka M; Wakasugi H
    Transplantation; 2005 Nov; 80(9):1145-52. PubMed ID: 16314778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of low dose of fludarabine and cyclophosphamide combined with donor NK Cells as a non-myeloablative conditioning regimen for the haploidentical hematopoietic stem cell transplantation in mice].
    Yu JP; Cao S; Xin N; An XM; Qi J; Ren XB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1013-8. PubMed ID: 17956681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA.
    Mackinnon S; Barnett L; Bourhis JH; Black P; Heller G; O'Reilly RJ
    Blood; 1992 Dec; 80(12):3235-41. PubMed ID: 1467526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
    Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
    Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism.
    Martin PJ
    Blood; 1996 Aug; 88(3):962-9. PubMed ID: 8704255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation.
    Luznik L; Engstrom LW; Iannone R; Fuchs EJ
    Biol Blood Marrow Transplant; 2002; 8(3):131-8. PubMed ID: 11939602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
    Martin PJ
    J Exp Med; 1993 Aug; 178(2):703-12. PubMed ID: 8101864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Marrow Graft-Versus-Host Disease in Major Histocompatibility Complex-Matched Murine Reduced-Intensity Allogeneic Hemopoietic Cell Transplantation.
    Shahin K; Mattar Z; Silveira P; Hsu WH; Bendall L; Hart D; Bradstock KF
    Transplantation; 2017 Nov; 101(11):2695-2704. PubMed ID: 28319565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR; Majewski D
    Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR; Taylor PA; Fitzsimmons WE; Vallera DA
    J Immunol; 1994 Aug; 153(4):1836-46. PubMed ID: 7519216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.